Schrodinger Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Schrodinger Inc 's ROA in the second quarter of 2026?
Schrodinger Inc recorded a cumulative net loss of $-54 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -8.19%.

However, within the Healthcare sector 281 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3356, from total ROA ranking in the first quarter of 2026 at 3908.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-6.95 %	-14.65 %	1.7 %	17.06 %	20 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-54	-103	-103	-176	-181
Return On Assets (TTM)	-8.19 %	-15.32 %	-14.69 %	-25.15 %	-26.83 %
SDGR's Total Ranking	# 3356	# 3908	# 3634	# 3685	# 3774
Total Assets (TTM) in million	640	634	726	654	688
Seq. Total Assets Change	0.98 %	-12.67 %	11.09 %	-5.02 %	-7.37 %
Seq. Net Income Change	-	-	-	-	-

SDGR's 5 Years Annual ROA >> Back to SDGR Management Effectiveness >> Compare SDGR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 97
Sector	# 282
Overall	# 3101

Return On Assets Statistics
High	Average	Low
8.76 %	-12.47 %	-26.66 %
(Jun 30 2023)		(Jun 30 2024)

News about Schrodinger Inc Return on Assets ROA

Schrödinger Set to Showcase Promising Preclinical Data on SGR-3515 and PRMT5-MTA at EORTC-NCI-AACR Symposium Amid Im...

Schrödinger Set to Showcase Promising Preclinical Data on SGR-3515 and PRMT5-MTA at EORTC-NCI-AACR Symposium Amid Impressive Revenue Growth In an exciting development within the biopharmaceutical sector, Schrödinger Inc. (Nasdaq: SDGR) has announced it will present new preclinical data regarding its investigational compounds SGR-3515 and the PRMT5-MTA inhibitor program at the esteemed 36th EORTC-NCI-AACR Symposium for Molecular Targets and Cancer Therapeutics, scheduled to occur from October 23-25, 2024, in Barcelona, Spain. This symposium, a key event for oncology researchers and professionals, will provide an excellent platform for Schrödinger to share its latest advancements. The presentation will delve into the characterization of SGR-3515, a novel Wee1/Myt1 inhibitor, emphasizing its potential role in enhancing therapeutic strategies through the regulation of the cell cycle. The insights presented are anticipated to shed light on the drug s preclinical efficacy in oncology models, positioning Schrödinger at the forefront of innovative cancer research.Concurrently, Schrödinger has reported significant financial performance, marking a year-on-year increase in revenue of 31.67% for Q2 2024. This robust sales growth notably surpasses the average revenue growth of 11.15% reported by its competitors during the same quarter. While the company continues to navigate a landscape marked by challenges, including recorded net losses, it has outpaced many of its rivals, heralding a promising trajectory for both its financial health and drug development initiatives.

Financial Statements
Schrodinger Inc 's Assets	$ 640 million	SDGR's Balance sheet
Schrodinger Inc 's Income	$ 6 million	Quarterly SDGR's Income Statement
SDGR's Income by Division		See SDGR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	12.02 %	3.95 %	17.15 %	-13.94 %	-7.66 %
Total Assets in million	800	714	687	586	681
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-103	-187	41	-149	-101
Annual Return On Assets	-12.91 %	-26.21 %	5.93 %	-25.45 %	-14.86 %

SDGR's 5 Years Annual ROA >> Back to SDGR Management Effectiveness >> Compare SDGR ROA to its Competitors

More Return On Assets Ratios
SDGR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SDGR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SDGR's Competitors
Subscribers only: Roa for Schrodinger Inc 's Suppliers
Subscribers only: Return On Assets for SDGR's Customers

You may also want to know
SDGR's Roi	SDGR's Inventory Turnover Ratio	SDGR's Growth Rates	SDGR's Dividend Comparisons
	SDGR's Profitability Ratios	SDGR's Asset Turnover Ratio	SDGR's Dividend Growth
SDGR's Roe	SDGR's Valuation Ratios	SDGR's Financial Strength Ratios	SDGR's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-09T00:12:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.